Expression of insulin-like growth factor-II mRNA-binding protein-3 as a marker for predicting clinical outcome in patients with esophageal squamous cell carcinoma

Takata,Akihiro; Takiguchi,Shuji; Okada,Kaoru; Takahashi,Tsuyoshi; Kurokawa,Yukinori; Yamasaki,Makoto; Miyata,Hiroshi; Nakajima,Kiyokazu; Mori,Masaki; Doki,Yuichiro

doi:10.3892/ol.2014.2465

Expression of insulin-like growth factor-II mRNA-binding protein-3 as a marker for predicting clinical outcome in patients with esophageal squamous cell carcinoma

Authors:
- Akihiro Takata
- Shuji Takiguchi
- Kaoru Okada
- Tsuyoshi Takahashi
- Yukinori Kurokawa
- Makoto Yamasaki
- Hiroshi Miyata
- Kiyokazu Nakajima
- Masaki Mori
- Yuichiro Doki
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka 565‑0871, Japan, Department of Surgery, Nishinomiya Municipal Central Hospital, Nishinomiya, Hyogo 663-8014, Japan
Published online on: August 20, 2014 https://doi.org/10.3892/ol.2014.2465
Pages: 2027-2031

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Insulin‑like growth factor‑II mRNA‑binding protein‑3 (IMP3) is an important factor in carcinogenesis, although its clinical significance in esophageal squamous cell carcinoma (ESCC) remains unknown. The present study investigated the associations between IMP3 expression and the clinicopathological parameters. IMP3 expression was assessed in 191 resected ESCC specimens, and the associations between IMP3 expression in ESCC, the clinicopathological parameters and patient prognosis were examined. Using immunohistochemistry, 113 (59.2%) tumors were identified as IMP3‑positive. IMP3 positivity correlated significantly with high pathological (p)Stage, pT stage and pN stage. The IMP3‑positive patients exhibited a poorer prognosis compared with the IMP3‑negative patients. In univariate analyses, histology [hazard ratio (HR), 1.94; 95% confidence interval (CI), 1.18‑3.49; P=0.0082], pT (HR, 2.34; 95% CI, 1.55‑3.62; P<0.0001), pN (HR, 2.85; 95% CI, 1.81‑4.69; P<0.0001), lymphatic invasion (HR, 2.08; 95% CI, 1.26‑3.70; P=0.0036), venous invasion (HR, 1.79; 95% CI, 1.21‑2.64; P=0.0039), neoadjuvant chemotherapy (NAC) (HR, 2.01; 95% CI, 1.35‑3.00; P=0.0005) and IMP3 expression (HR, 2.12; 95% CI, 1.40‑3.29; P=0.0003) were significantly associated with overall survival. Using multivariate analyses, histology (HR, 1.87; 95% CI, 1.13‑3.29; P=0.014), pN (HR, 2.19; 95% CI, 1.36‑3.66; P=0.0010), NAC (HR, 1.88; 95% CI, 1.24‑2.86; P=0.0028) and IMP3 expression (HR, 1.84; 95% CI, 1.18‑2.93; P=0.0064) were significant prognostic factors. IMP3 may therefore be a prognostic factor for patients with ESCC who have undergone a curative resection.

View Figures

View References

1	Shimada H, Nabeya Y, Okazumi S, et al: Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery. 133:486–494. 2003.
2	Tamoto E, Tada M, Murakawa K, et al: Gene-expression profile changes correlated with tumor progression and lymph node metastasis in esophageal cancer. Clin Cancer Res. 10:3629–3638. 2004.
3	Nielsen J, Christiansen J, Lykke-Andersen J, et al: A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 19:1262–1270. 1999.
4	Mueller-Pillasch F, Pohl B, Wilda M, et al: Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev. 88:95–99. 1999.
5	Yaniv K and Yisraeli JK: The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene. 287:49–54. 2002.
6	Gu L, Shigemasa K and Ohama K: Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer. Int J Oncol. 24:671–678. 2004.
7	Hammer NA, Hansen T, Byskov AG, et al: Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction. 130:203–212. 2005.
8	Hoffmann NE, Sheinin Y, Lohse CM, et al: External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer. 112:1471–1479. 2008.
9	Jiang Z, Chu PG, Woda BA, et al: Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 7:556–564. 2006.
10	Li D, Yan D, Tang H, et al: IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol. 16:3499–3506. 2009.
11	Okada K, Fujiwara Y, Nakamura Y, et al: Oncofetal protein, IMP3, a potential marker for prediction of postoperative peritoneal dissemination in gastric adenocarcinoma. J Surg Oncol. 105:780–785. 2012.
12	Simon R, Bourne PA, Yang Q, et al: Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not. Hum Pathol. 38:1178–1183. 2007.
13	Xu H, Bourne PA, Spaulding BO and Wang HL: High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol. 38:555–563. 2007.
14	Yantiss RK, Woda BA, Fanger GR, et al: KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 29:188–195. 2005.
15	Zheng W, Yi X, Fadare O, et al: The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol. 32:304–315. 2008.
16	Doyle GA, Betz NA, Leeds PF, et al: The c-myc coding region determinant-binding protein: a member of a family of KH domain RNA-binding proteins. Nucleic Acids Res. 26:5036–5044. 1998.
17	Gress TM, Müller-Pillasch F, Geng M, et al: A pancreatic cancer-specific expression profile. Oncogene. 13:1819–1830. 1996.
18	Liao B, Hu Y, Herrick DJ and Brewer G: The RNA-binding protein IMP3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem. 280:18517–18524. 2005.
19	Runge S, Nielsen FC, Nielsen J, et al: H19 RNA binds four molecules of insulin-like growth factor II mRNA-binding protein. J Biol Chem. 275:29562–29569. 2000.
20	Mueller F, Bommer M, Lacher U, et al: KOC is a novel molecular indicator of malignancy. Br J Cancer. 88:699–701. 2003.
21	Sobin LH, Gospodarowicz MK and Wittekind C: Oesophagus including oesophagogastric junction. International Union Against Cancer (UICC) TNM classification of Malignant Tumors. 7th edition. Wiley-Blackwell; New York, NY: pp. 66–72. 2009
22	Hansen TV, Hammer NA, Nielsen J, et al: Dwarfism and impaired gut development in insulin-like growth factor II mRNA-binding protein 1-deficient mice. Mol Cell Biol. 24:4448–4464. 2004.
23	Chao W and D’Amore PA: IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev. 19:111–120. 2008.
24	Foulstone E, Prince S, Zaccheo O, et al: Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol. 205:145–153. 2005.
25	Vikesaa J, Hansen TV, Jønson L, et al: RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J. 25:1456–1468. 2006.
26	Jeng YM, Wang TH, Lu SH, Yuan RH and Hsu HC: Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinoma. Br J Surg. 96:66–73. 2009.
27	Pryor JG, Bourne PA, Yang Q, et al: IMP3 is a novel progression marker in malignant melanoma. Mod Pathol. 21:431–437. 2008.
28	Yoshino K, Motoyama S, Koyota S, et al: Identification of insulin-like growth factor 2 mRNA-binding protein 3 as a radioresistance factor in squamous esophageal cancer cells. Dis Esophagus. Sep 18–2012.(Epub ahead of print).
29	Nischalke HD, Schmitz V, Luda C, et al: Detection of IGF2BP3, HOXB7, and NEK2 mRNA expression in brush cytology specimens as a new diagnostic tool in patients with biliary strictures. PLoS One. 7:e421412012.
30	Kono K, Iinuma H, Akutsu Y, et al: Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med. 10:1412012.